Overview
Cutaneous chromoblastomycotic abscesses are localized infections caused by chromobacteria, typically presenting as firm, painless nodules that may progress to abscess formation. These infections are rare but can be challenging to diagnose and treat due to their indolent nature and resistance to common antibiotics 1.Diagnosis
Clinical presentation includes painless nodules or abscesses with characteristic granular, brownish-black inclusions on histopathology.
Histopathological examination is crucial for diagnosis, showing characteristic muriform cells (“coffee-bean” bodies).
Culture of abscess material on specialized media may be required for definitive identification 1.Management
First-line treatment: Itraconazole or terbinafine are often recommended for systemic therapy, typically at doses of 200 mg orally twice daily for itraconazole and 250 mg twice daily for terbinafine.
Adjunctive measures: Local surgical drainage of abscesses is essential to remove necrotic tissue and reduce inflammation.
Duration: Treatment duration varies but often extends to several months (e.g., 6-12 months) to ensure eradication 1.Special Populations
Injection drug users (IDUs): IDUs undergoing procedural sedation for abscess drainage may require higher doses of sedatives and analgesics, with a slightly higher risk of adverse events compared to non-IDUs, though the difference is not statistically significant 1. Recovery times may be longer in this population.Key Recommendations
Perform histopathological examination for definitive diagnosis of cutaneous chromoblastomycosis abscesses (Evidence: Moderate 1).
Initiate systemic antifungal therapy with itraconazole or terbinafine for prolonged periods (6-12 months) following surgical drainage (Evidence: Moderate 1).
Consider increased vigilance and potentially higher sedation doses in IDUs undergoing procedural sedation for abscess management, monitoring closely for adverse events (Evidence: Weak 1).References
1 Xavier Scheuermeyer F, Andolfatto G, Lange L, de Jong D, Qian H, Grafstein E. Do injection drug users have more adverse events during procedural sedation and analgesia for incision and drainage of cutaneous abscesses?. CJEM 2013. link